Says it sees supply of 1.3bn doses by the end of 2021
- 100m doses this year upon approval
- showed strong immunogenicity in younger, older adults
- vaccine well tolerated across all populations
- 11,000 participants dosed with its BNT162B2
- Will share T cell immune response data in the near future
Positive vaccine news tends to give risk a boost - its doing just that as I update
